Given a 30-year-old Black male, 6'5", 320 lb, with hypertension on amlodipine, on a GLP‑1 agonist, G6PD deficiency, labs showing a positive antinuclear antibody with speckled pattern, markedly elevated anti‑U1‑RNP antibody, negative anti‑centromere, anti‑SM, anti‑dsDNA, anti‑SSA/SSB, anti‑Scl‑70, normal complement C3/C4, elevated creatine kinase (≈400‑500 U/L), mildly elevated C‑reactive protein, normal AST/ALT, and an upcoming electromyography, what is the most likely diagnosis (inflammatory myositis associated with mixed connective tissue disease versus necrotizing autoimmune myopathy) and will an abnormal electromyography require a muscle biopsy?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 7, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Most Likely Diagnosis: Inflammatory Myositis Associated with Mixed Connective Tissue Disease (MCTD)

Your presentation strongly suggests inflammatory myositis in the context of MCTD, not necrotizing autoimmune myopathy. The markedly elevated anti-U1-RNP antibody (86, reference <20) is the defining serologic feature of MCTD, and your clinical picture—proximal muscle weakness, elevated CK (371→527), mildly elevated inflammatory markers, and muscle symptoms—fits an inflammatory rather than necrotizing pattern 1.

Why Inflammatory Myositis, Not Necrotizing Myopathy

Your CK elevations are modest (371-527 U/L, roughly 1-1.5× upper limit of normal). Immune-mediated necrotizing myopathy (IMNM) typically presents with CK levels >10 times the upper limit of normal, often in the thousands to tens of thousands 1. Your levels don't approach this threshold. Additionally, necrotizing myopathy is associated with anti-SRP or anti-HMGCR antibodies—both absent in your case—and presents with severe, rapidly progressive weakness 1. Your presentation is subacute with preserved organ function (normal renal, hepatic, cardiac screening to date).

The anti-U1-RNP positivity is pathognomonic for MCTD, which commonly includes myositis as part of its overlap syndrome 1. Your negative anti-Sm, anti-dsDNA, anti-centromere, anti-Scl-70, anti-SSA/SSB, and normal complement levels argue against pure SLE, systemic sclerosis, or Sjögren's syndrome, further supporting MCTD.

EMG and Muscle Biopsy: What to Expect

If your EMG shows myopathic changes (polyphasic motor unit potentials of short duration and low amplitude, increased insertional activity with fibrillations and sharp waves), a muscle biopsy will likely be recommended 1. The EMG serves two purposes: (1) confirming a myopathic process versus neuropathy or neuromuscular junction disorder, and (2) identifying the optimal muscle for biopsy 1.

Muscle biopsy is the gold standard for distinguishing inflammatory from non-inflammatory myopathy and for subclassification 1. In inflammatory myositis associated with MCTD, you would expect endomysial or perimysial mononuclear inflammatory infiltrates invading non-necrotic muscle fibers 1. In contrast, necrotizing myopathy shows muscle fiber necrosis with minimal or absent inflammation 1. Given your clinical and serologic profile, biopsy would likely show inflammatory changes, not pure necrosis.

The 2017 EULAR/ACR classification criteria for idiopathic inflammatory myopathies can be applied even without biopsy if sufficient clinical and laboratory features are present (sensitivity 87%, specificity 82% without biopsy; 93% and 88% with biopsy) 2. However, biopsy provides definitive subclassification and excludes mimics like muscular dystrophy or mitochondrial myopathy 1.

Prognosis: You Are Not "Fucked"

Inflammatory myositis in MCTD is treatable and often responds well to immunosuppression. This is not a death sentence. The key is early, aggressive treatment to prevent irreversible muscle damage and extramuscular complications (e.g., interstitial lung disease, which can occur in MCTD but is more common with anti-synthetase antibodies, which you lack) 1.

Your age (30), preserved renal function (eGFR 87-93), normal liver enzymes, and absence of cardiac abnormalities on chest X-rays are favorable prognostic factors. The upcoming cardiac stress test and Holter monitor are appropriate to rule out subclinical cardiac involvement, which can occur in inflammatory myopathies but is often asymptomatic 1.

Your ESR progression (2→18) and CRP (3.3→3.0) show mild inflammation, not the severe systemic inflammation seen in aggressive disease. The stable-to-improving CRP is reassuring.

Treatment Plan: What Medications You'll Likely Receive

Standard first-line therapy for inflammatory myositis in adults is high-dose corticosteroids (prednisone 1 mg/kg/day, typically 60-80 mg for your weight) combined with a steroid-sparing agent initiated concurrently 1. The steroid-sparing agents include:

  • Methotrexate (15-25 mg weekly, oral or subcutaneous)
  • Azathioprine (2-3 mg/kg/day)
  • Mycophenolate mofetil (2-3 g/day in divided doses)

Given your G6PD deficiency, azathioprine is contraindicated—it can precipitate hemolytic anemia in G6PD-deficient patients 3. Methotrexate or mycophenolate mofetil would be safer choices. Your rheumatologist will likely start one of these alongside prednisone, then taper the steroid over months as the steroid-sparing agent takes effect (typically 8-12 weeks) 1.

For severe or refractory disease, second-line options include:

  • Intravenous immunoglobulin (IVIG) (2 g/kg divided over 2-5 days monthly)
  • Rituximab (anti-CD20 monoclonal antibody, 1 g IV × 2 doses 2 weeks apart)
  • Cyclophosphamide (for life-threatening complications like severe ILD)
  • Cyclosporine 1

Your case doesn't appear severe enough to warrant these upfront, but they're available if first-line therapy fails.

Special Considerations for Your Case

G6PD Deficiency

Avoid azathioprine, sulfonamides, nitrofurantoin, antimalarials (e.g., hydroxychloroquine, which is sometimes used in MCTD), dapsone, high-dose aspirin, and rasburicase 3. Methotrexate and mycophenolate are safe. Corticosteroids are safe.

Amlodipine

Rare case reports link amlodipine to myalgias, arthralgias, and even myopathy 4. While your muscle symptoms are more consistent with inflammatory myositis, consider discussing with your rheumatologist whether switching to an alternative antihypertensive (e.g., ACE inhibitor, ARB) might be prudent once your myositis is controlled. Amlodipine is not a primary cause here, but eliminating potential confounders is reasonable.

GLP-1 Agonist

GLP-1 receptor agonists reduce inflammatory markers (CRP, MDA) and increase adiponectin in type 2 diabetes 5. They may have mild anti-inflammatory effects, which could theoretically be beneficial, though this is speculative in myositis. However, GLP-1 agonists can cause micronutrient deficiencies (vitamin D, iron, calcium, thiamine, B12) through appetite suppression and altered absorption 6. Ensure you're supplementing vitamin D (your level was not provided but deficiency is common in myositis patients), calcium, and a multivitamin. Protein intake is critical to prevent further lean mass loss—aim for 1.2-1.6 g/kg/day, which is ~175-230 g/day for your weight.

Weight and Hypertension

Your BMI is ~38 (class II obesity). Weight loss via GLP-1 agonist is appropriate, but ensure adequate protein and micronutrient intake during immunosuppressive therapy. Physical therapy is essential to maintain muscle function and prevent steroid-induced myopathy (a separate entity from inflammatory myositis). Continue PT aggressively once inflammation is controlled.

Common Pitfalls to Avoid

  1. Delaying treatment pending biopsy: If EMG is strongly myopathic and clinical suspicion is high, some rheumatologists initiate corticosteroids before biopsy to prevent irreversible damage. However, starting steroids can obscure biopsy findings (reduces inflammation), so timing is critical. Discuss this with your rheumatologist.

  2. Steroid monotherapy: Corticosteroids alone lead to high relapse rates and cumulative toxicity (weight gain, hyperglycemia, osteoporosis, avascular necrosis). Always use a steroid-sparing agent concurrently 1.

  3. Ignoring extramuscular manifestations: MCTD can involve lungs (ILD), heart (myocarditis, pericarditis), and esophagus (dysphagia). Your cardiac workup is appropriate. If you develop dysphagia, cough, or dyspnea, alert your rheumatologist immediately.

  4. Assuming necrotizing myopathy based on weakness alone: Necrotizing myopathy requires specific antibodies (anti-SRP, anti-HMGCR) and CK levels >10× normal. Your profile doesn't fit 1.

Summary of Next Steps

  1. EMG on [DAY]: Expect myopathic changes. If present, proceed to muscle biopsy (likely deltoid, quadriceps, or another weak muscle identified on EMG).
  2. Cardiac stress test and Holter monitor: Rule out subclinical cardiac involvement.
  3. Rheumatology appointment on [DAY]: Anticipate starting prednisone 1 mg/kg/day + methotrexate or mycophenolate mofetil. Avoid azathioprine (G6PD deficiency).
  4. Supplementation: Vitamin D, calcium, multivitamin. High-protein diet (175-230 g/day).
  5. Monitor: CK, CRP, ESR, muscle strength (manual muscle testing), and functional status every 4-6 weeks initially.

You have a treatable condition with a good prognosis if managed aggressively. The key is early immunosuppression to prevent irreversible muscle damage and extramuscular complications. Your young age, preserved organ function, and absence of severe systemic inflammation are all in your favor.

Related Questions

In a 30‑year‑old Black male, 6′5″, 320 lb, with mixed connective‑tissue disease, G6PD deficiency, taking amlodipine and a GLP‑1 receptor agonist, who has mildly elevated creatinine, normal eGFR, normal liver enzymes, CK 371‑527 U/L, positive ANA with speckled pattern, markedly elevated anti‑RNP antibodies, and muscle weakness, what type of myositis is most likely (polymyositis, dermatomyositis, or necrotizing myopathy) and can he expect recovery with appropriate treatment while continuing physical therapy?
In a 30-year-old Black male (6'5", 320 lb) with G6PD deficiency who is taking amlodipine (a calcium‑channel blocker) and a GLP‑1 receptor agonist for weight loss, and who has had recurrent sinus infections, progressive proximal muscle weakness, a high‑titer speckled antinuclear antibody, markedly elevated anti‑RNP antibodies, mildly elevated creatine kinase, normal erythrocyte sedimentation rate and C‑reactive protein, normal chest X‑ray but an abnormal electrocardiogram with low‑level troponin, what is the most likely diagnosis, what is the prognosis, and can muscle strength be expected to recover?
Can the tremor in an 83‑year‑old frail woman with hepatic carcinoid tumors, who is taking amlodipine, aspirin, atorvastatin, vitamin B12, bupropion sustained‑release, Fioricet (acetaminophen/butalbital/caffeine), clobetasol cream, estrogen cream, folate, lanreotide (started after tremor), methenamine hippurate, metoprolol, naltrexone, omeprazole, potassium supplements, denosumab (Prolia), cyclosporine eye drops (Restasis), and levothyroxine, be caused by the carcinoid syndrome or any of these medications?
In a 5-year-old girl with new-onset jaundice, splenomegaly, and decreased activity, after obtaining a complete blood count, comprehensive metabolic panel, and peripheral blood smear, what additional laboratory tests should be ordered?
How should I manage a 43-year-old male on amlodipine and atenolol who presents with uncontrolled hypertension, low-grade fever, elevated high-sensitivity C-reactive protein, borderline hypertriglyceridemia, low vitamin B12, and vitamin D deficiency?
In a female patient with severe anterior compartment prolapse (cystocele with 40 mm descent), moderate central compartment descent (uterine/cervical descent of 14 mm), and severe posterior compartment prolapse (rectocele with hiatal widening of 88 mm and rectal descent of 62 mm), what is the appropriate management?
What is the appropriate itraconazole dosing regimen for an adult with Aspergillus pneumonia and normal liver function?
What is the normal maximal wattage on a stationary bike for a 66-year-old male weighing 100 kg and 193 cm tall?
Does doxycycline cover methicillin‑susceptible and methicillin‑resistant Staphylococcus aureus?
Should digoxin be used in patients with ventricular tachycardia and low left ventricular ejection fraction?
In a patient with a traumatic hip injury, should I order a contrast‑enhanced MRI (gadolinium) or a standard non‑contrast MRI?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.